Clinical Trial

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

Study acronym: DREAMM-10
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Protocol Amendment History 1 change
notable Trial sites expanded: 174 -> 181 locations 2026-04-23
Trial Details
NCT Number NCT06679101
Lead Sponsor GlaxoSmithKline
Conditions Multiple Myeloma, Newly Diagnosed Multiple Myeloma
Enrollment 520 participants
Start Date 2024-12-16
Primary Completion 2031-04-28 (estimated)
Study Completion 2031-04-28 (estimated)
Updated on ClinicalTrials.gov 2026-04-22